GemPharmatech Joins Shonan Health Innovation Park, Expanding and Strengthening Research Support in Japan

FOR IMMEDIATE RELEASE

GemPharmatech Joins Shonan Health Innovation Park, Expanding and Strengthening Research Support in Japan

Global genetically engineered mouse model innovator strengthens presence in leading pharmaceutical research hub

FUJISAWA CITY, JAPAN — April 1, 2025 — GemPharmatech, a global leader in genetically engineered mouse models and preclinical research services, today announced its official entry into Shonan Health Innovation Park (Shonan iPark). This strategic move marks a significant milestone in the company's expansion into the Japanese market and reinforces it commitment to advancing biomedical research and innovation worldwide.

The partnership with Shonan Health Innovation Park represents a significant step forward in GemPharmatech's global growth strategy. Japan's renowned expertise in the life sciences, and pharmaceutical development, provides an ideal backdrop for the company's continued expansion of its genetically engineered mouse model and preclinical services portfolio. The park's strategic environment will allow GemPharmatech to cultivate meaningful relationships and collaborations with leading research institutions, pharmaceutical firms, and biotechnology innovators.

"Japan has long been a key player in global biomedical research," said Dr. Xiang Gao, Founder and Chairman of GemPharmatech. "We are honored and excited to join the innovation-driven ecosystem of Shonan iPark and look forward to fostering closer collaborations with Japan's academic and industry leaders."

By establishing a dedicated presence within Shonan Health Innovation Park, GemPharmatech aims to support Japan’s research organizations and expedite their research and drug development processes.

Researchers will now have immediate access to the company's unparalleled library of more than 25,000 genetically engineered mouse models. Furthermore, GemPharmatech offers a comprehensive selection of preclinical services to help researchers accelerate scientific discovery and therapeutic development. This direct access will empower Japanese scientists to conduct more sophisticated translational research, develop cutting-edge therapeutics, and ultimately bring potentially life-saving treatments to patients faster and more efficiently than ever before.

For collaboration inquiries, please contact: globalservice@gempharmatech.com

About GemPharmatech:

GemPharmatech is a global contract research organization specializing in genetically engineered mouse models and preclinical services. With a commitment to scientific innovation, the company supports researchers worldwide in advancing medical discoveries.

Media Inquiries:

Jason Tyler, Associate Director of Branding & Marketing Communications

Email: Jason.tyler@gempharmatech.com